Roth Capital Partners acted as Sole Manager
for Unicycive Therapeutics, Inc. (Nasdaq:UNCY)
in its $25 Million IPO

For more information please contact:
Investment Banking
James Antonopoulos
Managing Director &
Head of Healthcare
Investment Banking
(646) 358-1906
Aparna Beeram
Vice President
(646) 358-1912
Equity Capital Markets
Aaron Gurewitz
Head of Equity
Capital Markets
(949) 720-5703
Nazan Akdeniz
Senior Vice President
(949) 720-5740
Lou Ellis
Senior Vice President
(949) 720-5739

Transaction Information
Unicycive Therapeutics, Inc., a clinical stage biotechnology company developing therapies for patients with kidney disease, announced the closing of its underwritten initial public offering of 5,000,000 units at a public offering price per unit of $5.00. Each unit consists of one share of common stock and four-fifths of a warrant to purchase one share of common stock. The warrants have an exercise price of $6.00 per share and are exercisable for a period of five years after the issuance date. All of the units are being offered by Unicycive. In addition, Unicycive has granted the underwriters a 45-day option to purchase up to an additional 750,000 shares of its common stock and/or warrants to purchase up to an additional 600,000 shares of its common stock, at the initial public offering price, less the underwriting discounts and commissions.

In connection with the offering, the Company's common stock has been approved for listing on The Nasdaq Capital Market. The shares started trading on the Nasdaq Capital Market on July 13, 2021, under the ticker symbol "UNCY." The offering closed on July 15, 2021.

The gross proceeds to Unicycive from the offering, before deducting the underwriting discounts and commissions and offering expenses, are $25 million.

Roth Capital Partners acted as the sole manager for the offering.

About Unicycive Therapeutics, Inc.
Unicycive is a biotechnology company developing novel treatment for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia, with an NDA filing expected in 2021. UNI-494 is a new chemical entity with issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. For more information, please visit (Source: Company Press Release | 06.13.21)

About Roth Capital Partners
Roth Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, Roth provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, Roth is privately-held and employee owned, and maintains offices throughout the U.S. For more information on Roth, please visit

About Roth  |  Investment Banking  |  Capital Markets  |  Institutional Sales & Trading
Research  |  Corporate Services  |  Corporate Access & Conferences  |  Press Room

Date of Announcement: 08.19.21
The material, information and  facts discussed in this announcement other than the information regarding Roth Capital Partners, LLC ("Roth") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of Roth. Copyright 2021.